Retatrutide
⥠Quick Description & Benefits
Triple hormone receptor agonist (GLP-1 / GIP / glucagon) by Eli Lilly. Code name LY3437943. Phase 3 as of 2024. Not yet FDA approved â available only through clinical trials.
Key Benefits:
- â Triple action: stimulates GLP-1 and GIP receptors (satiety, insulin sensitization) plus glucagon receptors (increased energy expenditure, hepatic fat clearance)
- â Up to 22.8-24.2% body weight loss at 48 weeks in Phase 2 (8-12 mg doses)
- â Most potent fat-loss of any approved/approval-pending incretin to date
- â Significantly reduces liver fat in MASLD/MASH patients
- â Improves triglycerides, LDL, and cardiovascular risk markers
đŦ Detailed Function & Research
Mechanism & Function
Triple hormone receptor agonist (GLP-1 / GIP / glucagon) by Eli Lilly. Code name LY3437943. Phase 3 as of 2024. Not yet FDA approved â available only through clinical trials. It operates by stimulating specific cellular receptors, activating downstream enzymatic pathways and physiological repair mechanisms without widespread systemic disturbance.
Research & Scientific Support
Extensive pre-clinical and translational models demonstrate consistent receptor affinity and regenerative signalling across controlled studies.
Protocol Notes:
- âĸ As of early 2025, Retatrutide is still in Phase 3 â NO legal commercial form exists
- âĸ Any site selling "retatrutide" to consumers is selling an unapproved, unverified molecule. Quality and identity cannot be confirmed.
- âĸ ~6 day half-life supports once-weekly dosing.
- âĸ The glucagon-receptor component is what separates it from Tirzepatide: adds genuine energy expenditure, not just appetite reduction.
- âĸ Does NOT stack with Semaglutide or Tirzepatide â overlapping GLP-1/GIP action provides no additive benefit and increases intolerance.
- âĸ Expected FDA approval (if successful): 2026-2027 under trade name likely "Triplenica" or similar.
𧎠Dosing & Reconstitution Calculator
Calculate syringe units or suggest optimal reconstitution solution volume
Volume Guideline: Most subcutaneous injections should fall between 10 and 20 units for optimal comfort, though certain peptides may feel better at volumes up to 60 units. Increments start at 1.0ml in 0.5ml steps.
đ Research Papers & Clinical Studies
Peer-reviewed research and indexed publications for Retatrutide:
đ Dosing & Administration
Phase 2 escalation (LY3437943): âĸ Weeks 1-4: 2 mg once weekly âĸ Weeks 5-8: 4 mg once weekly âĸ Weeks 9-12: 6 mg once weekly âĸ Weeks 13-16: 8 mg once weekly âĸ Weeks 17-24: 9 mg once weekly âĸ Weeks 25+: 12 mg once weekly (maximum Phase 2 dose) Phase 3 trials (TRIUMPH program) are ongoing with similar titration. No legal commercial version exists yet.
đ Pairs Well With
â ī¸ Side Effects
- ! Nausea, diarrhea, vomiting, constipation (dose-dependent, most common)
- ! Abdominal pain, dyspepsia
- ! Injection site reactions
- ! Decreased appetite
- ! Rare: pancreatitis, gallbladder disease reported in trials
- ! Contraindicated with history of medullary thyroid carcinoma or MEN2 (class effect)